OncLive TV

Dr Shreenivas on the FDA Approval of Penpulimab Plus Chemo for Frontline Non-Keratinizing Nasopharyngeal Carcinoma

May 2nd 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.

Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular Lymphoma

May 2nd 2025

Vivek G Patel, MD, discusses the comparative efficacy and safety profiles of mosunetuzumab and epcoritamab in follicular lymphoma.

Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant

May 1st 2025

Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.

Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

May 1st 2025

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Dr André on the Safety Profile of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic CRC

May 1st 2025

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.

Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer

April 30th 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.

Dr Randall on the Use of Osteosarcoma Spheroid Models to Streamline Preclinical Therapeutic Development

April 30th 2025

R. Lor Randall, MD, FASCO, discussed the development and application of three-dimensional spheroid models for high-throughput drug screening in osteosarcoma research.

Dr Chan on Unmet Needs Addressed by the FDA Approval of Cabozantinib for pNET and epNET

April 30th 2025

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Dr Shadman on the Utility of a Meta Analysis of BTK Inhibitors in R/R CLL

April 30th 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Dr Chase on Considering Patient Preferences for Treatment Planning in Gynecologic Oncology

April 30th 2025

Dana M. Chase, MD, discusses how patient preferences can inform treatment planning in gynecologic oncology.

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

April 30th 2025

Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma

April 30th 2025

Stergios J. Moschos, MD, discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma.

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

April 30th 2025

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

Dr Pimenta on Adipogenesis Defects Characteristic of Dedifferentiated Liposarcoma

April 30th 2025

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

April 30th 2025

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Dr Boffa on Factors Informing Early-Stage Esophageal Cancer Management

April 29th 2025

Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.

Dr Lamanna on Considerations for Pirtobrutinib Use in Pretreated CLL

April 29th 2025

Nicole Lamanna, MD, shares key considerations for the use of pirtobrutinib in the management of chronic lymphocytic leukemia.